Pharma & Biopharma Manufacturing
8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026
Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...
July 29, 2026 | Analysis
Harbour BioMed and Sinopharm Form Strategic Alliance to Accelerate Innovative Biologics
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunolo...
July 29, 2026 | News
AsymBio Breaks Ground on Shanghai R&D Hub to Accelerate Biologics Development
AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.S...
July 29, 2026 | News
Asymchem Achieves First USFDA Inspection Milestone for Carbapenem API Manufacturing Facility
Asymchem, a leading global contract development and manufacturing organization (CDMO), announced that its dedicated carbapenem API manufacturing facil...
July 28, 2026 | News
7 Countries Competing to Be the Region’s Next Biomanufacturing Hub
A siting decision for a biomanufacturing facility is one of the most expensive commitments a company makes, and it is made against a fifteen to twenty year...
July 27, 2026 | Analysis
Nova Biomedical Expands Cell Line Development Portfolio with NanoCellect Technology Acquisition
Nova Biomedical announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Bio...
July 27, 2026 | News
The APAC CDMO Shortlist: 10 CDMOs to Watch Through 2028
There is a version of this list that writes itself. Rank the region’s contract manufacturers by installed litres, put Samsung Biologics at the top, a...
July 24, 2026 | Analysis
Samsung Bioepis Secures Exclusive Commercial Rights to Nectin-4 ADC Candidate SBE303
Ÿ Under the agreement, Samsung Bioepis will obtain exclusive commercial licensing rights to SBE303, an ADC candidate currently in joi...
July 24, 2026 | News
Lonza and Engitix Partner to Advance Next-Generation ECM-Targeted ADCs
Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC de...
July 22, 2026 | News
Samsung Biologics Launches CHF 1.46B All-Cash Bid to Acquire PolyPeptide
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury share...
July 21, 2026 | News
From Capacity to Capability: The New Race to Lead ASEAN Biomanufacturing
ASEAN is entering a new phase of biopharmaceutical manufacturing, where simply building more capacity will no longer guarantee competitiveness. As ...
July 17, 2026 | Expert Insight
Australia Builds a New Radiopharmaceutical Gateway from Research to Patient Care
First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. Patient care...
July 17, 2026 | News
China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?
THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...
July 16, 2026 | Analysis
ACROBiosystems Secures Japan PMDA Confirmation for GMP-Grade IL-15 Used in Cell Therapy Manufacturing
ACROBiosystems has officially received the "Material Suitability Confirmation for Regenerative Medicine Products" (Certificate No.: 薬機審長発第47号...
July 16, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
